Comparison of full-fat corn germ, whole cottonseed, and tallow as fat sources for lactating dairy cattle.

Twenty-four multiparous Holstein cows (124 +/- 39 d in milk; 682 +/- 72 kg of body weight) were used in 6 simultaneous 4 x 4 Latin squares to evaluate full-fat corn germ as a fat source for lactating dairy cows. Experimental diets were a control (containing 28% ground corn, 23% alfalfa hay, 19% wet corn gluten feed, and 10% corn silage, dry matter basis), and 3 diets with either whole cottonseed (WCS), tallow (TAL), or full-fat corn germ (FFCG) added to provide 1.6% supplemental fat. Cows were fed twice daily for ad libitum intake. Dry matter intake, milk yield, and energy-corrected milk did not differ among diets. Efficiency of milk production (energy-corrected milk/dry matter intake) was greater for cows fed WCS than for cows fed the control, TAL, or FFCG. Milk fat percentage from cows fed FFCG was less than that of cows fed WCS or the control, but was similar to that of cows fed TAL. Milk protein percentage was less for cows fed FFCG than for those fed the control. Total saturated fatty acids were less in milk from cows fed fat sources, and cows fed WCS and TAL had greater saturated fatty acids in milk than did cows fed FFCG. Unsaturated fatty acids were greater in milk from cows fed FFCG than in milk from cows fed the control, WCS, or TAL. The cis-9, trans-11 conjugated linoleic acid content was greater in milk from cows fed WCS, TAL, and FFCG than from cows fed the control, and it was greater in milk from cows fed FFCG than in milk from cows fed WCS or TAL. These results indicate that FFCG can be used effectively as a fat source in diets for lactating dairy cattle.

Plasma metabolites of receiving heifers and the relationship between apparent bovine respiratory disease, body weight gain, and carcass characteristics.

Six hundred sixty-five crossbred beef heifers initially weighing 225 kg were used in a completely randomized design to measure plasma glucose, lactate, and urea N concentrations at time of initial processing, determine the incidence of apparent bovine respiratory disease (BRD) in receiving cattle, and evaluate the effect of apparent BRD on subsequent cattle growth and carcass characteristics. Heifers were processed within 24 h of arrival, and processing included vaccination against common viral and clostridial diseases, recording rectal temperature, and sampling whole blood for subsequent measurement of plasma glucose, lactate, and urea concentrations. Heifers were monitored for clinical signs of apparent BRD, including depression, lethargy, anorexia, coughing, rapid breathing, and nasal or ocular discharge. Heifers exhibiting signs of apparent BRD received antibiotic therapy, and the number of times a heifer was treated for apparent BRD was recorded. Following the 36-d receiving period, heifers were transported to native grass pastures and allowed to graze for 136 d. At the end of the grazing season, heifers were transported to a commercial feedlot where they were adapted to a common finishing diet offered for ad libitum consumption. Following the 124-d finishing period, heifers were slaughtered and carcass data were collected. Heifers treated for apparent BRD had decreased plasma glucose (linear, P < 0.01), lactate (linear, P < 0.01), and urea N concentrations (linear, P < 0.06) measured at time of initial processing. Rectal temperature measured at time of initial processing tended to be greater (linear, P < 0.11) for heifers treated for apparent BRD. Heifers treated for apparent BRD during the receiving period had decreased overall ADG (linear, P < 0.10), final BW (linear, P < 0.01), HCW (linear, P < 0.01), fat thickness (linear, P < 0.01), and marbling score (linear, P < 0.03). These data suggest that initial plasma glucose and lactate concentrations might be affected by the health status of receiving cattle and that increased incidence of apparent BRD in cattle decreases ADG and carcass quality.

Regulation of cholesterol 7 alpha-hydroxylase in the liver. Purification of cholesterol 7 alpha-hydroxylase and the immunochemical evidence for the induction of cholesterol 7 alpha-hydroxylase by cholestyramine and circadian rhythm.

Two cholesterol 7 alpha-hydroxylase isozymes were purified from liver microsomes of cholestyramine-treated female rats by using anion exchange high performance liquid chromatography. These two cytochrome P-450 isozymes were similar in electrophoretic mobility, immunocross-reactivity, and Vmax but differed in Km for cholesterol, turnover number, and charges. Antibody against the major isozyme was raised in rabbit. This antibody specifically inhibited microsomal cholesterol 7 alpha-hydroxylase activity. Immunoblot of microsomal polypeptides indicated that microsomal cholesterol 7 alpha-hydroxylase enzyme levels were increased in parallel with cholesterol 7 alpha-hydroxylase activity upon the treatment of rats with diet supplemented with cholestyramine. Both cholesterol 7 alpha-hydroxylase activity and enzyme levels were drastically reduced immediately after the removal of cholestyramine from the diet. Cholesterol 7 alpha-hydroxylase activity was also detected in the microsomes of kidney, heart, and lung in about 7-27% of the level found in the liver. 3-Methylcholanthrene treatment induced cholesterol 7 alpha-hydroxylase activity and enzyme level. In contrast, pregnenolone-16 alpha-carbonitrile or dexamethasone treatment greatly depressed enzyme and activity in rats. Cholesterol 7 alpha-hydroxylase enzyme level was 2-3-fold higher in liver microsomes of rats maintained under the reversed light cycle than under the normal light cycle. In genetically obese Zucker rats, cholesterol 7 alpha-hydroxylase activity and enzyme level did not respond to the change in the light cycle, however, were induced to the same levels as in the lean rats by cholestyramine treatment. This study provided the first direct evidence that the bile acid feedback regulation and circadian rhythm of microsomal cholesterol 7 alpha-hydroxylase activity involved the induction of cholesterol 7 alpha-hydroxylase enzyme level.

Chronic obstructive pulmonary disease.

While the prospects of "curing" a patient of emphysema, chronic bronchitis, or asthma are poor, prompt institution of appropriate drug therapy and adjunctive measures can keep the patient from becoming a respiratory cripple.

The viking seismic experiment.

A three-axis short-period seismometer is now operating on Mars in the Utopia Planitia region. The noise background correlates well with wind gusts. Although no quakes have been detected in the first 60 days of observation, it is premature to draw any conclusions about the seismicity of Mars. The instrument is expected to return data for at least 2 years.

Bronchodilator effect of a new oral beta adrenoreceptor stimulant, Th1165a. A comparison with metaproterenol sulfate.

In a single-blind study the short-term effects of oral administration of Th1165a (5, 10, 15, and 20 mg), metaproterenol sulfate (Alupent) (20 mg), and placebo on ventilatory function, pulse rate, and systolic and diastolic blood pressure were compared over a period of six hours in ten patients with stable, reversible obstructive airway disease. Both Th1165a (5, 10, 15 and 20 mg) and metaproterenol administration caused significant bronchodilation of rapid onset (30 minutes), but the bronchodilator effect of Th1165a (10, 15, and 20 mg) was greater and lasted longer (six hours vs three hours) than that of metaproterenol. A dose-dependent bronchodilator effect was recognizable after administration of Th1165a. The 20-mg dose of metaproterenol sulfate and the 5-mg and 10-mg doses of Th1165a produced minimal side effects. Larger doses (15 and 20 mg of Th1165a caused significant increases in pulse rate. Mild and transient tremors were the most common side effect after administration of Th1165a.

Chronic obstructive airway diseases. Current concepts in diagnosis and comprehensive care.

Physicians and paramedical personnel often find the early diagnosis and differentiation of obstructive airway diseases to be a challenging problem. The history and physical examination are often not enough to allow the physician to detect either the presence of, or determine the type of, disease present. Patterns of pulmonary function abnormality to determine the presence of obstructive or restrictive defects are discussed. Guidelines useful in the differentiation of obstructive airway diseases are presented. Once a patient with COAD is assessed, the physician needs to outline a therapeutic program after establishing goals with the patient. These goals include (1) improved ability for the patient to achieve relief from symptoms and (2) improved capacity to carry out the activities of daily living. The therapeutic modalities available for the comprehensive care of patients with COAD are discussed. These include general factors such as patient and family education, avoidance of smoking and other inhaled irritants, avoidance of infection, a minimum stress environment, high fluid intake, and proper nutrition. The appropriate use of the medications most commonly employed in the teatment of these patients, eg, bronchodilators, expectorants, antimicrobials, corticosteroids, cromolyn, digitalis, and diuretics, are individually discussed. The use of such respiratory therapy techniques as aerosol therapy, intermittent positive pressure breathing, and oxygen therapy are considered. Application of the specialty of rehabilitation medicine to patients with obstructive airway disease is described. This includes physical therapy with breathing retraining, clapping and postural drainage, and exercise reconditioning, occupational therapy with attention to energy conservation in activities of daily living, psychological considerations, and vocational rehabilitation. Definite benefits that can be demonstrated if the physician employs this type of systematic respiratory care program include a decrease in the frequency and duration of hospital admissions, socioeconomic gains from reduced hospitalizations, a reduction in anxiety, depression and somatic concern, the return of patients to positions of employment and the establishment of a better quality of life. Persistence in making sure the patient continues in a systematic program, including both pharmacological and nonpharmacological modalities, may be the means of assuring maintenance or even improvement in his health. The day-to-day treatment for the majority of patients should remain in the hands of the primary physician. However, community resources must be established to allow the primary physician to provide these patients with adequate comprehensive respiratory care. Development of three levels of care (the primary physician, community respiratory rehabilitation units, and the regional respiratory center) should make superior respiratory care available to every patient with obstructive airway disease.

Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline.

A double-blind crossover comparison was made of the effect of orally administered terbutaline (a new adrenergic drug with major action on beta2-receptors), ephedrine, and placebo in 15 patients with obstructive airways disease. Serial determination of ventilatory tests, arterial gas tensions, arterial blood pressure, ECG, blood chemistries, and urinalysis were made before and after administration of the tested drug. Terbutaline (5 mg) was found to be an effective bronchodilator with minimal side effects and an earlier onset and longer duration of action than ephedrine (25 mg).